BACKGROUND: Females with atrial fibrillation (AF) are at increased risk for ischemic stroke but have been under-represented in AF ablation cohorts. Whether the incidence of TE in women after catheter ablation is higher is unknown. We aimed to analyze the predictive value of thromboembolic scores and other clinical variants for thromboembolism (TE) after AF catheter ablation, separately in women and men. METHODS: TE was combined endpoint of early (within first month) and late (during long-term follow-up) stroke, transient ischemic attack, or systemic embolism. Oral anticoagulation was prescribed for 6 months after catheter ablation and discontinued if CHADS2 was <2 and no AF recurrences were documented. RESULTS: The study population (n = 2,069, 66 % male, 60 ± 10 years; 62 % paroxysmal AF) was followed for a median of 18 months (IQR 12-29). Overall 31 TE (1.5 %) occurred with 16 events within 30 days of ablation and 15 TE during the follow-up. Fourteen females (2.0 %) and 17 males (1.2 %) suffered TE (p = 0.128). On multivariate analysis, higher CHADS2 (HR 1.65, 95 % CI 1.10-2.47, p = 0.015), CHA2DS2-VASc (HR 1.42, 95 % CI 1.03-1.96, p = 0.034), R2CHADS2 (HR 1.76, 95 % CI 1.32-2.35, p < 0.001) scores, and eGFR <60 ml/min/1.73 m(2) (HR 3.95, 95 % CI 1.23-12.7, p = 0.021) were significantly associated with TE in men. In females, LV-EF (HR 0.95, 95 % CI 0.91-0.99, p = 0.021) and CHA2DS2-VASc score (HR 1.52, 95 % CI 1.01-2.28, p = 0.044) remained significant predictors for TE. CONCLUSION: TE rates after AF catheter ablation are low in both genders. In females, LV-EF and CHA2DS2-VASc score and in males all three scores and renal dysfunction were associated with TE.
BACKGROUND: Females with atrial fibrillation (AF) are at increased risk for ischemic stroke but have been under-represented in AF ablation cohorts. Whether the incidence of TE in women after catheter ablation is higher is unknown. We aimed to analyze the predictive value of thromboembolic scores and other clinical variants for thromboembolism (TE) after AF catheter ablation, separately in women and men. METHODS: TE was combined endpoint of early (within first month) and late (during long-term follow-up) stroke, transient ischemic attack, or systemic embolism. Oral anticoagulation was prescribed for 6 months after catheter ablation and discontinued if CHADS2 was <2 and no AF recurrences were documented. RESULTS: The study population (n = 2,069, 66 % male, 60 ± 10 years; 62 % paroxysmal AF) was followed for a median of 18 months (IQR 12-29). Overall 31 TE (1.5 %) occurred with 16 events within 30 days of ablation and 15 TE during the follow-up. Fourteen females (2.0 %) and 17 males (1.2 %) suffered TE (p = 0.128). On multivariate analysis, higher CHADS2 (HR 1.65, 95 % CI 1.10-2.47, p = 0.015), CHA2DS2-VASc (HR 1.42, 95 % CI 1.03-1.96, p = 0.034), R2CHADS2 (HR 1.76, 95 % CI 1.32-2.35, p < 0.001) scores, and eGFR <60 ml/min/1.73 m(2) (HR 3.95, 95 % CI 1.23-12.7, p = 0.021) were significantly associated with TE in men. In females, LV-EF (HR 0.95, 95 % CI 0.91-0.99, p = 0.021) and CHA2DS2-VASc score (HR 1.52, 95 % CI 1.01-2.28, p = 0.044) remained significant predictors for TE. CONCLUSION: TE rates after AF catheter ablation are low in both genders. In females, LV-EF and CHA2DS2-VASc score and in males all three scores and renal dysfunction were associated with TE.
Authors: Margaret C Fang; Daniel E Singer; Yuchiao Chang; Elaine M Hylek; Lori E Henault; Nancy G Jensvold; Alan S Go Journal: Circulation Date: 2005-09-12 Impact factor: 29.690
Authors: Hakan Oral; Aman Chugh; Mehmet Ozaydin; Eric Good; Jackie Fortino; Sundar Sankaran; Scott Reich; Petar Igic; Darryl Elmouchi; David Tschopp; Alan Wimmer; Sujoya Dey; Thomas Crawford; Frank Pelosi; Krit Jongnarangsin; Frank Bogun; Fred Morady Journal: Circulation Date: 2006-08-14 Impact factor: 29.690
Authors: Jelena Kornej; Gerhard Hindricks; Jedrzej Kosiuk; Arash Arya; Philipp Sommer; Daniela Husser; Sascha Rolf; Sergio Richter; Christopher Piorkowski; Thomas Gaspar; Gregory Y H Lip; Andreas Bollmann Journal: Circ Arrhythm Electrophysiol Date: 2013-09-18
Authors: Jonathan P Piccini; Susanna R Stevens; YuChiao Chang; Daniel E Singer; Yuliya Lokhnygina; Alan S Go; Manesh R Patel; Kenneth W Mahaffey; Jonathan L Halperin; Günter Breithardt; Graeme J Hankey; Werner Hacke; Richard C Becker; Christopher C Nessel; Keith A A Fox; Robert M Califf Journal: Circulation Date: 2012-12-03 Impact factor: 29.690
Authors: A John Camm; Sana M Al-Khatib; Hugh Calkins; Jonathan L Halperin; Paulus Kirchhof; Gregory Y H Lip; Stanley Nattel; Jeremy Ruskin; Amitava Banerjee; Dan Blendea; Eduard Guasch; Matthew Needleman; Irina Savelieva; Juan Viles-Gonzalez; Eric S Williams Journal: Am Heart J Date: 2012-08-03 Impact factor: 4.749
Authors: V Roldán; F Marín; S Manzano-Fernandez; H Fernández; P Gallego; M Valdés; V Vicente; G Y H Lip Journal: Thromb Haemost Date: 2013-03-21 Impact factor: 5.249
Authors: Alan S Go; Margaret C Fang; Natalia Udaltsova; Yuchiao Chang; Niela K Pomernacki; Leila Borowsky; Daniel E Singer Journal: Circulation Date: 2009-03-02 Impact factor: 29.690
Authors: Melanie Gunawardene; S Willems; B Schäffer; J Moser; R Ö Akbulak; M Jularic; C Eickholt; J Nührich; C Meyer; P Kuklik; S Sehner; V Czerner; B A Hoffmann Journal: Clin Res Cardiol Date: 2016-07-19 Impact factor: 5.460
Authors: Jelena Kornej; Gerhard Hindricks; M Benjamin Shoemaker; Daniela Husser; Arash Arya; Philipp Sommer; Sascha Rolf; Pablo Saavedra; Arvindh Kanagasundram; S Patrick Whalen; Jay Montgomery; Christopher R Ellis; Dawood Darbar; Andreas Bollmann Journal: Clin Res Cardiol Date: 2015-04-17 Impact factor: 5.460